Three-Dose Regimen of MRKAd5+6 Trigene (V526) in Healthy Adults (V526-001)(COMPLETED)

A Phase I Dose Ranging Study of the Safety, Tolerability, and Immunogenicity of a 3-Dose Regimen of the MRKAd5 HIV-1 Trigene and the MRKAd6 HIV-1 Trigene Vaccines Alone and in Combination in Healthy Adults

A study to assess the general safety and tolerability of the administration of the 3-dose regimen of the MRKAd5+6 trigene vaccine

Inclusion Criteria:

• Subject has negative tests for HIV, Hepatitis B, and Hepatitis C within 60 days of injection
• Subject agrees to use an acceptable method of birth control through week 52 of the study

Exclusion Criteria:

• Subject has been given immune globulin or blood products within 30 days of first dose of study vaccine
• Subject has been vaccinated with a live virus vaccine within 30 days or an inactivated vaccine within 5 days of first dose of study vaccine
• Subject has known or suspected impaired immune function
• Subject has participated in any other HIV vaccine trial
• Female subject is pregnant or breastfeeding